{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003346","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2026-05-13T11:31:16+00:00","discovered_at":"2026-05-13T11:35:00.272589+00:00","generated_at":"2026-05-13T11:38:01.542316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement","bullets":["Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.","Net income $169.7M vs net loss $24.5M in Q1 2025; diluted EPS $0.87.","Moderna settlement: $950M noncontingent payment due July 2026; Arbutus expects ~$178.7M.","Cash, equivalents and marketable securities $95.2M as of March 31, 2026.","FDA granted Fast Track designation for imdusiran for chronic hepatitis B."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003346","json":"https://secwatch.observer/filing/0001171843-26-003346.json","markdown":"https://secwatch.observer/filing/0001171843-26-003346.md","text":"https://secwatch.observer/filing/0001171843-26-003346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/f8k_051226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:38:01.542316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72c9a989b0c96e942c1bd6bcf822faa832dd1c1d","claim":"Arbutus Biopharma Corp reported first quarter ended March 31, 2026 results: revenue $179.1 million, net income $169.7 million, EPS income of $0.88 per basic and $0.87 per diluted common share.","evidence_excerpt":"Revenue Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$179.1 million"},{"label":"Net income","value":"$169.7 million"},{"label":"EPS","value":"income of $0.88 per basic and $0.87 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9a6d46b2e3a8c55955c3df71104d8d5a84175f2b","claim":"Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.","evidence_excerpt":"Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Net income","value":"For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8"},{"label":"EPS","value":"income of $0.88 per basic and $0.87 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9a6d46b2e3a8c55955c3df71104d8d5a84175f2b","claim":"Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.","evidence_excerpt":"For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.87 per diluted common share, as compared to a net loss of $24.5 million, or a loss of $0.13 per basic and diluted common share, for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/0001171843-26-003346-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Net income","value":"For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8"},{"label":"EPS","value":"income of $0.88 per basic and $0.87 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}